Search

Tenders are invited for Procurement of enzyme replacement therapy for MPS type II(hunter sundrome). Opening date : 01 Dec 2020 Major organization : ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS) [...]

Tenders are invited for Procurement of enzyme replacement therapy Product Category: Miscellaneous goods Tender Type: Open tender Bid Validity(Days): 30 Period Of Work(Days): 45 Location: Aiims, new delhi Document Download [...]

Tenders are invited for Procurement of enzyme replacement therapy Product Category: Miscellaneous goods Tender Type: Open tender Bid Validity(Days): 30 Period Of Work(Days): 45 Location: Aiims, new delhi Document Download [...]

- Avalglucosidase alfa, an investigational enzyme replacement therapy for patients with Pompe disease, reaches its first important regulatory milestone - Pompe disease affects an estimated 50,000 people worldwide - Submission [...]

(GLOBE NEWSWIRE via COMTEX) -- EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease - Avalglucosidase alfa, an investigational enzyme [...]

Tenders are invited for Procurement of enzyme replacement therapy for mps type ii (hunter syndrome) Product Category: Miscellaneous goods Tender Type: Open tender Bid Validity(Days): 30 Period Of Work(Days): 45 [...]

London: UK Parliament has issued the following written answer: Answered on 14 September 2020 Enzyme replacement therapy for CLN2 (Batten disease) is available through a managed access agreement. In Batten [...]

Tenders are invited for Procurment of enzyme replacement therapy for mps type ii (hunter syndrome ) Product Category: Miscellaneous goods Tender Type: Open tender Bid Validity(Days): 30 Period Of Work(Days): [...]

(GLOBE NEWSWIRE via COMTEX) -- Sanofi's investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease - Avalglucosidase alfa showed a 2.4-point improvement in percent-predicted [...]

(GlobeNewswire) - Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease Virtual scientific session June 16, 2020, 8:00-9:00am ET/2:00-3:00pm CET Avalglucosidase alfa receives FDA [...]

(GLOBE NEWSWIRE via COMTEX) -- Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease - Virtual scientific session June 16, 2020, 8:00-9:00am ET/2:00-3:00pm CET [...]

Protalix BioTherapeutics and its partner Chiesi Global Rare Diseases, have submitted an application to the U.S. Food and Drug Administration (FDA) requesting the approval of PRX-102 (pegunigalsidase alfa), an investigational [...]

New Delhi, June 2 -- The latest report on Pompe Disease Market (by therapy type (enzyme replacement therapy and substrate reduction therapy), molecule type (biologics and small molecules), dosage form [...]

Protalix BioTherapeutics (NYSEMKT:PLX) announces positive results from a Phase 3 clinical trial, BRIDGE, evaluating enzyme replacement therapy pegunigalsidase alfa (PLX-102) in Fabry disease patients who previously received Takeda's (NYSE:TAK) Replagal [...]

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today announced the approval of its Clinical Trial [...]

AUSTIN, Texas, Apr 08, 2020 (GLOBE NEWSWIRE via COMTEX) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet [...]

SAN FRANCISCO, CA -- The following information was released by UCSF Medical Center: In Mouse Study, Stem Cells Migrated to Proper Locations in Fetal Brain and Body, Differentiated Into Cells [...]

The Cystic Fibrosis Foundation has reached an agreement with Synspira Therapeutics to support the further development of SNSP003, an enzyme replacement therapy (ERT) designed to treat malabsorption syndromes, including those [...]

Sanofi Genzymes next-generation enzyme replacement therapy (ERT), avalglucosidase alfa, safely halts disease progression in people with Pompe disease, according to interim data from two Phase 2 clinical trials. The trials [...]

FRAMINGHAM: Synspira Therapeutics has issued the following press release: Synspira Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare [...]

Bethesda, Md. -- The following information was released by the Cystic Fibrosis Foundation: Between 85 and 90 percent of people with CF are pancreatic insufficient. This occurs when thick, sticky [...]

-- Registry Study Will Provide Supplemental Information on Revcovi in a Post-Marketing Commitment Study -- GAITHERSBURG, Md. -- Leadiant Biosciences, Inc. announced it is conducting the Registry Study of Revcovi([R]) [...]

Daix: INVENTIVA has issued the following press release: Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, [...]

PARIS: Sanofi has issued the following press release: Olipudase alfa, an investigational recombinant human acid sphingomyelinase, demonstrated positive results in two separate clinical trials evaluating olipudase alfa for the treatment [...]

PARIS: Sanofi has issued the following press release: Olipudase alfa, an investigational recombinant human acid sphingomyelinase, demonstrated positive results in two separate clinical trials evaluating olipudase alfa for the treatment [...]

(GlobeNewswire) - Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency Acid sphingomyelinase deficiency (ASMD) is a rare, progressive and [...]

(GlobeNewswire) - Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency Acid sphingomyelinase deficiency (ASMD) is a rare, progressive and [...]

Sanofi (NASDAQ:SNY) has announced positive results from 2 clinical trials evaluating its enzyme replacement therapy, olipudase alfa, in patients with a acid sphingomyelinase deficiency (ASMD) A Phase 2/3 study, ASCEND, [...]

(GLOBE NEWSWIRE via COMTEX) -- Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency -- Acid sphingomyelinase deficiency (ASMD) is [...]

M2 PRESSWIRE-January 30, 2020-: Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency (C)1994-2020 M2 COMMUNICATIONS RDATE:30012020 * Acid sphingomyelinase [...]

The 'Novel Enzyme Technologies for Pharmaceutical Applications' report has been added to ResearchAndMarkets.com's offering. This study discusses the novel enzyme technologies for enzyme discovery and improvements such as directed mutagenesis, [...]

NEW YORK: Reportlinker has issued the following press release: The current study discusses the novel enzyme technologies for enzyme discovery and improvement such as directed mutagenesis, metagenomics, artificial intelligence and [...]

AUSTIN: Aeglea BioTherapeutics, Inc. has issued the following press release: Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet [...]

AUSTIN, Texas, Jan 13, 2020 (GLOBE NEWSWIRE via COMTEX) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet [...]

REDWOOD CITY: Codexis, Inc. has issued the following press release: Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestle Health Science, a globally [...]

(GlobeNewswire) - Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestl Health Science, a globally recognized leader in the field of nutritional science, [...]

REDWOOD CITY, Calif., Jan 10, 2020 (GLOBE NEWSWIRE via COMTEX) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestle Health Science, a [...]

BOSTON: Entrada Therapeutics has issued the following press release: Entrada Therapeutics, Inc. a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today [...]

PORTLAND: Allied Market Research has issued the following press release: Allied Market Research recently published a report, titled, 'Cystic Fibrosis (CF) Therapeutics Market by Drug Class (Pancreatic Enzyme Supplements, Mucolytic, [...]

NEW YORK: Reportlinker has issued the following press release: Hunter Syndrome Treatment Market Size, Share & Trend Analysis By Treatment (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), By Region, And [...]

DUBLIN: Research and Markets has issued the following press release: The 'Cystic Fibrosis Drugs Market By Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements, and Others), By Route of [...]

MARBLEHEAD: Allievex Corporation has issued the following press release: Allievex Corporation ('Allievex'), a clinical-stage biotechnology company founded by Pappas Capital, today announced the completion of a Series A financing co-led [...]

AzurRx BioPharma, Inc. (NASDAQ:AZRX) a company specializing in the development of non-systemic, announced that it has dosed the first patients in its Phase 2 clinical trial to investigate in combination [...]

NEW YORK, Oct 15, 2019 (GLOBE NEWSWIRE via COMTEX) -- -- First cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI) treated in dose escalation study of MS1819-SD in [...]

DUBLIN: Research and Markets has issued the following press release: The 'Cystic Fibrosis Drugs Market By Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements, and Others), By Route of [...]

DUBLIN -- The 'Cystic Fibrosis Drugs Market By Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements, and Others), By Route of Application (Oral, Inhalation and Intravenous), By Region - [...]

M2 PRESSWIRE-October 10, 2019-: Cystic Fibrosis Drugs MarketExpected to Grow with a CAGR of 10% During the Forecast Period, 2019-2025 (C)1994-2019 M2 COMMUNICATIONS RDATE:10102019 The 'Cystic Fibrosis Drugs Market By [...]

ROCKVILLE, MD -- The following information was released by the Regulatory Affairs Professionals Society: By Zachary Brennan The US Food and Drug Administration (FDA) on Wednesday finalized guidance to help [...]

LONDON -- The following information was released by the National Institute for Health and Clinical Excellence (UK): A drug which slows the decline of a rare inherited condition affecting children [...]

BEIJING & SHANGHAI: CANbridge Pharmaceuticals Inc. has issued the following press release: CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and [...]